Although states of metabolic dysfunction including insulin resistance, obesity, and T2D are associated with increased levels of circulating chemerin and CMKLR1 expression in SAT and VAT [402,403,404,405,406,407,408,409], there remain controversies concerning whether chemerin upregulation participates in disease pathogenesis or represents a compensatory mechanism. This evidence concerns the gene RARRES2 and Insulin resistance.